NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zeta Global Holdings Corp. (NYSE: ZETA) between February 27, 2024 and November 13, 2024, both dates inclusive (the “Class Period”), of the important January 21, 2025 lead plaintiff deadline. SO WHAT: If you purchased Zeta securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Zeta class action, go to https://rosenlegal.com/submit-form/?case_id=31333 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 21, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Zeta used two-way contracts to artificially inflate financial results; (2) Zeta engaged in round trip transactions to artificially inflate financial results; (3) Zeta utilized predatory consent farms to collect user data; (4) these consent farms have driven almost the entirety of Zeta’s growth; and (5) as a result of the foregoing, defendants’ positive statements about Zeta’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Zeta class action, go to https://rosenlegal.com/submit-form/?case_id=31333 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.comIsraeli troops forcibly remove staff and patients from northern Gaza hospital, officials say
The tax exemptions provided by the state to households and businesses have reached 18.8 billion euros, an amount corresponding to 28.2% of total tax revenue. Without tax exemptions, tax revenues would have reached €85.5 billion, enabling governments to pursue social policy with targeted actions and permanent measures. According to the Ministry of National Economy and Finance, the value of tax exemptions grew by €3.26 billion last year. The increase in the amount from €12.8 billion in 2021 to €15.5 billion in 2022 is mainly due to the adjustment of the property rates used for taxable purposes (known as “objective values”) and the increase in the tax-free threshold for donations and parental benefits to €800,000. In 2023, tax exemptions numbered 1,106, up from 1,064 in 2022.The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progressed or have prolonged stable disease on single agent PD-1 inhibitors The primary objective of the Phase 1b study is to assess preliminary efficacy by objective response rate (ORR) and duration of response (DOR) per RECIST version 1.1 and secondarily immune-related response via iRECIST The study will recruit patients from four sites across Israel HAMILTON, Bermuda, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that the Israeli Ministry of Health (IMOH) has approved the use of Low Volume UNO (LV UNO) in a Phase 1b clinical trial of LV UNO in combination with anti-PD-1 therapy. The trial will be conducted at four sites in Israel and patient screening will begin in the first quarter of 2025. The Phase 1b trial (NCT05351502) is a clinical proof-of-concept trial that will assess the intratumoral administration of LV UNO in patients with unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic lesions, who have shown disease progression or prolonged stable disease (≥ 12 weeks) after receiving a single agent anti-PD-1 containing treatment. The trial, which is expected to enroll up to 20 subjects, is designed to assess the preliminary efficacy of LV UNO by objective response rate (ORR) and duration of response (DOR) per RECIST v1.1 and secondarily immune-related response via iRECIST. Safety and tolerability of LV UNO in combination with anti-PD-1 therapy, as well as its potential to enhance the type, density, and distribution of immune cells within the tumor microenvironment will also be observed. Topline data from the Phase 1b portion of the study are anticipated in the second half of 2025. "We are excited to initiate the Phase 1b trial of LV UNO, a potentially groundbreaking solid tumor treatment approach, in combination with PD-1 inhibitors," said Dr. Jedidiah Monson, Chief Medical Officer of Beyond Cancer. "In preclinical studies, a single dose of UNO has been shown to increase PD-L1 expression and improve overall survival in animal models compared to anti-PD-1 alone. Further, Phase 1a human data that demonstrated immune system activation were presented at ASCO's Key Opinion Leader Event held in June 2024. We look forward to the Phase 1b trial results to establish the basis of further investigation of UNO in combination with PD-1 inhibitors." "The initiation of the Phase 1b trial represents a major step forward in our vision for personalized cancer treatment. We see UNO as a complementary therapy for future cancer treatment paradigms, particularly for patients with anti-PD-1 refractory or resistant disease, potentially offering more patients access to effective treatment," stated Dr. Selena Chaisson, Chief Executive Officer, and Director of Beyond Cancer. About Nitric Oxide Nitric Oxide (NO) is a potent molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens. About UNO Therapy for Solid Tumors Cancer is the second leading cause of death globally, with tumor metastases responsible for approximately 90% of all cancer-related deaths. Current cancer treatment modalities generally include chemotherapy, immunotherapy, radiation, and/or surgery. Ultra-high concentration Nitric Oxide (UNO) therapy is a completely new approach to preventing relapse or metastatic disease. In vitro murine data show that local tumor ablation with UNO stimulates an anti-tumor immune response in solid tumor cancer models. Beyond Cancer, Ltd. believes that UNO has the potential to prevent relapse or metastatic disease with as little as a single 5-minute treatment and with limited toxicity or off-target effects. About Beyond Cancer, Ltd. Beyond Cancer, Ltd. is a development-stage biopharmaceutical and medical device company utilizing ultra-high concentration nitric oxide (UNO) via a proprietary delivery platform to treat primary tumors and prevent metastatic disease. Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer. A first-in-human study is underway in patients with solid tumors. Beyond Cancer is also conducting preclinical studies of UNO in multiple solid tumor models to inform additional treatment protocols. For more information, visit www.beyondcancer.com . Forward Looking Statements This press release contains "forward-looking statements" concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words "expects," "plans," "anticipates," "believes" "expects," "intends," "looks forward," "projects," "goal," "assumes," "targets" and similar expressions and/or the use of future tense or conditional constructions (such as "will," "may," "could," "should" and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials concerning the ultra-high concentration nitric oxide product candidate; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for the ultra-high concentration nitric oxide product candidate; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; obtaining, maintaining and protecting intellectual property utilized by products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the "Risk Factors" section of Beyond Air, Inc.'s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air, Inc.'s website. Beyond Cancer and Beyond Air undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law. CONTACTS: Corey Davis, PhD LifeSci Advisors, LLC Cdavis@lifesciadvisors.com (212) 915-2577 Matt Johnson, Head of Corporate Development & Strategy Beyond Cancer, Ltd. Mjohnson@beyondcancer.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Wabtec: Time To Blow Off Some SteamCo-founder and current CEO Scott Knoll to transition to Executive Chairman NEW YORK , Dec. 9, 2024 /PRNewswire/ -- Guideline.ai , a leading provider of advertising data and planning technology, announced that Vincent Mifsud will become its new Chief Executive Officer, succeeding the company's co-founder, Scott Knoll , who will now serve as Executive Chairman. Mifsud brings decades of experience building high-performing teams and impactful technology products. Most recently, Mr. Mifsud was the Global President of Enghouse Systems Limited, a leading global B2B enterprise software company with a suite of vertically focused software products. The company grew significantly during his time at Enghouse, expanding to approximately 1,800 employees and over $350 million in revenue. Prior to joining Enghouse, he was CEO of Scribble Technologies, a leading content marketing SaaS provider, and held executive roles with high-growth companies such as Genesis, Pivotal and Rand Technologies. Mifsud's track record improving customer outcomes through technology and process improvement, along with his experience serving marketers, makes him a perfect fit to join the Guideline team for the next step of its accelerated growth journey. " Scott Knoll's founding vision for Guideline is more relevant now than ever," said Vince Mifsud . "I look forward to working with him and the talented team at Guideline to build on an exciting foundation of the world's most comprehensive and accurate media investment data and the leading media planning application used by the majority of top global advertisers." Knoll founded Guideline in 2020 to improve the media investment ecosystem through new applications of data science. This thesis led to Guideline's acquisitions of Standard Media Index and SQAD in 2022, and Lumina in 2023. Following the acquisitions, Guideline has introduced exciting innovations into the marketplace, including new insights into programmatic media investment activity and a next-generation ad planning software platform. In his role as Executive Chairman, Knoll will continue to drive the Company's integrated product vision and support its customer relationships. "Vince brings a wealth of experience helping businesses achieve their potential and is deeply aligned with our company's vision, values, and growth strategy," said Knoll. "I look forward to working with Vince in support of our customers and partners as we continue to build innovative new products and solutions for the advertising ecosystem." About Guideline Guideline, a leading provider of advertising data and planning technology, has become the world's most trusted authority on media investment and intelligence. The company was formed through the acquisitions of Standard Media Index, SQAD, and Lumina. With its market-leading media planning platform, industry-best ad market data and unrivaled customer service, Guideline effectively meets the evolving needs of today's marketing, media and investment professionals. To learn more about Guideline, visit guideline.ai or follow us on LinkedIn. View original content to download multimedia: https://www.prnewswire.com/news-releases/guideline-announces-vincent-mifsud-as-ceo-302326355.html SOURCE GuidelineUniversity System of Georgia to ban DEI, commit to neutrality, teach Constitution
A Port Kembla cafe owner is fighting the Wollongong City Council decision forcing it to close its doors in a few months. Black Friday Sale Subscribe Now! Login or signup to continue reading Rachel Weekes runs Cakes by Rach at the Military Road cafe, on a site that has seen various other establishments serving food since 1965. In February, the council ordered the cafe to close as it was located in a residential R2 zone where such activities were prohibited. That closure was delayed, and a new development control order was issued stating that the cafe had to close by the end of February. In the meantime, Ms Weeks lodged a development application to allow the cafe to continue operating, which was rejected in September because the council deemed the "existing uses" section of the planning legislation could not be used to override the zoning issue. Ms Weekes has lodged a review of the knockback, which the council will decide on by mid-March. "It's incredibly stressful," Ms Weekes said of the experience. "Not just for me, but it's stressful for the staff, especially as we go into Christmas. We've got no idea what to expect at the other side of that. "And financially it also hurts. We've had to pay for submissions of applications, and the planning proposal itself would be another one of those, and that's quite costly." As well as the review of the development application, she was also looking to submit a planning proposal to the council and said the council was conducting "an independent review of the whole situation". "The general manager will take a look at that and decide whether or not there is something else that maybe could be done or changed," Ms Weeks said. "Essentially he just wants to see all of the detail." Ms Weeks said she felt confident the result of all the work and stress will be that the cafe can remain open. "We're a single property and we've actually been operating for two years," she said. "So it's not a matter of trying to understand the impact of the business on the community or the environment because that's very clear already. "We've had no issues with any of that over the last two years. "So I'd be fairly confident the outcome of a planning proposal would be would be a positive one. "I just need to be allowed to continue to trade while that process is worked through." A statement from Wollongong City Council suggested the February close is still very much on the cards. "The cafe operator and landlord have been advised in writing that council will not enforce the development control order to stop the use of the premises as a restaurant or cafe until the end of February 2025," the council spokesperson said. "The operator of the cafe must comply with the development control order from March 1, 2025." The spokesperson confirmed an independent review is underway. "A separate review in response to specific complaints from the proprietor, not the historic use of the site, is ongoing," the spokesperson said. "Council will advise the proprietor when this has been completed." I'm an award-winning senior journalist with the Illawarra Mercury and have well over two decades' worth of experience in newspapers. I cover the three local councils in the Illawarra for the Mercury, state and federal politics, as well as writing for the TV guide. If I'm not writing, I'm reading. I'm an award-winning senior journalist with the Illawarra Mercury and have well over two decades' worth of experience in newspapers. I cover the three local councils in the Illawarra for the Mercury, state and federal politics, as well as writing for the TV guide. If I'm not writing, I'm reading. More from Latest News Newsletters & Alerts DAILY Today's top stories curated by our news team. Also includes evening update. WEEKDAYS Grab a quick bite of today's latest news from around the region and the nation. WEEKLY The latest news, results & expert analysis. WEEKDAYS Catch up on the news of the day and unwind with great reading for your evening. WEEKLY Love footy? We've got all the action covered. WEEKLY Every Saturday and Tuesday, explore destinations deals, tips & travel writing to transport you around the globe. WEEKLY Get the latest property and development news here. WEEKLY Find out what's happening in local business. WEEKLY Going out or staying in? Find out what's on. WEEKDAYS Sharp. Close to the ground. Digging deep. Your weekday morning newsletter on national affairs, politics and more. TWICE WEEKLY Your essential national news digest: all the big issues on Wednesday and great reading every Saturday. WEEKLY Get news, reviews and expert insights every Thursday from CarExpert, ACM's exclusive motoring partner. TWICE WEEKLY Get real, Australia! Let the ACM network's editors and journalists bring you news and views from all over. AS IT HAPPENS Be the first to know when news breaks. DAILY Your digital replica of Today's Paper. Ready to read from 5am! DAILY Test your skills with interactive crosswords, sudoku & trivia. Fresh daily!
SANTA CLARA, Calif. (AP) — After three straight losses, including back-to-back blowouts , the San Francisco 49ers needed a get-right game. The Chicago Bears helped provide just that. Brock Purdy carved up Chicago's defense to lead San Francisco to its best offensive output of the season and the defense dominated the Bears in a 38-13 win Sunday that looked a lot more like the team that went to the Super Bowl last season than the one that has struggled in 2024. “I think just the biggest thing was just getting some energy and momentum,” Purdy said. “This league is hard. It’s tough. If you don’t have momentum or energy and belief within a building, it can be really tough.” The problem for San Francisco (6-7) is it might be too late to salvage its playoff hopes. Three blown fourth-quarter leads to division rivals and the lopsided losses at Green Bay and Buffalo the previous two weeks leave the Niners two games out of the playoffs with only four games to go. They might need to win out to get back to the postseason for a fourth straight season, and even then they could need some help because their three division losses will make it tough to win any tiebreakers in the tightly packed NFC West. “If we win every single game, I think we’ve put ourselves in a very good position to either win the division or somehow sneak our way into playoff contention,” tight end George Kittle said. “I thought everyone’s focused on this one week. ... Forget the whole season whether you’ve played like crap the entire season, whether you’ve had missed opportunities, or whether you have a bunch of touchdowns. Whatever it is, flush all that and just focus on this one game.” Big plays. The Niners repeatedly gashed the Bears for big plays as the passing game looked as good as it has all season. Purdy had eight completions go for at least 20 yards — tied for the most in any game for the 49ers since at least 1991 — with Kittle catching four of them, Isaac Guerendo two and one each for Deebo Samuel and Jauan Jennings. Kickoffs. Jake Moody attempted two line-drive kicks as San Francisco tried to pin Chicago deep instead of allowing a touchback. But both kicks landed shy of the landing zone at the 20, giving the Bears the ball at the 40. DL Yetur Gross-Matos. The Niners have been struggling to generate a pass rush with Nick Bosa sidelined, but Gross-Matos made a big impact on Sunday. He had a career-high three sacks in the game after coming into the game with just one this season. S Ji'Ayir Brown. The second-year safety lost his starting job with the return of Talanoa Hufanga from a wrist injury. Brown played 15 defensive snaps in a spot role and was beat on a TD pass to Rome Odunze in his limited action. Guerendo has a sprained foot and will be evaluated later this week to see if he can play. ... OL Ben Bartch will likely go on IR after suffering a high ankle sprain Sunday. ... LB Dre Greenlaw could return this week for the first time since tearing his Achilles tendon in the Super Bowl. ... DL Nick Bosa (hip, oblique) and LT Trent Williams (ankle) will be evaluated this week but there is no timeline on when they will return. ... LG Aaron Banks cleared the concussion protocol and should play this week. ... LB Dee Winters (ankle), S Malik Mustapha (chest, shoulder) and LB Demetrius Flannigan-Fowles are day-to-day. 305 — The 49ers outgained the Bears by 305 yards in the first half for the ninth best advantage in a first half since at least 1991. The 319 yards for San Francisco were the most by any team in a first half this season and the 4 yards allowed were the fewest. The 49ers host the Los Angeles Rams on Thursday night. AP NFL: https://apnews.com/hub/NFL
Kitchens will lead Tar Heels in Fenway Bowl against UConn. Another ex-Browns coach is standing by
WALGREENS is shuttering another store, forcing local customers to transfer prescriptions and head elsewhere for necessities. The location is now added to a list of over 1,200 planned closures throughout the next year. Shoppers who frequent the Walgreens at 4014 Plaza Goldorado Circle in Cameron Park, California , about 32 miles east of Sacramento, will be affected. It permanently closes its doors on January 27, 2025, per the Sacramento Business Journal . Two other Walgreens locations on 1401 Broadway and 7155 24th Street nearby will also close in the New Year , making it a total of three in the area axed for customers. The Broadway location shuts down on January 23, and the 24th Street spot on January 29. Read More on Walgreens Walgreens said there were "increased regulatory and reimbursement pressures" as far as the reasoning behind the closures in an email to the Sacramento Business Journal. It deemed the locations as underperforming and considered costs like rent , supplies, and staff salaries in its decision. Employees will have opportunities to transfer to other Walgreens stores. Customers at the Cameron Park store will also have their prescriptions transferred to a CVS pharmacy nearby, according to Walgreens. Most read in Money CLOSING TIME Walgreens locations have been slowly closing this year, and confirmation that there would be at least 1,200 axed from the chain's retail footprint was confirmed by Walgreens Boots Alliance CEO Tim Wentworth in October. Wentworth noted that the closures would take place over three years as part of a $1 billion cost-cutting program, which also sees the firing of several mid-level executives. At least 500 closures are planned for 2025 alone. The CEO seeks to bring back Walgreens' market value, as it was once worth $100 billion in 2015. As of 2024, the company is valued at $7.5 billion, a significant decrease. Market shares were also down about 70% this year, per data from The Wall Street Journal . We recognize where we are is a turnaround. "This turnaround will take time, but we are confident it will yield significant financial and consumer benefits over the long term," Wentworth noted in a press release earlier this year. POTENTIAL BUYER That turnaround could be sooner than expected if Walgreens Boots Alliance is bought out by private equity firm Sycamore Partners. If it goes through, Walgreens customers could see changes to the pharmacy chain's operations, as it would be taken off the public market. The deal hasn't been finalized but could be confirmed early next year. Sycamore recently bought other giants like Staples for $6.9 billion in 2017. Walgreens has also been catching attention for other reasons recently. Read More on The US Sun A $10 bathroom item went viral recently at Walgreens for performing better and being three times cheaper than a name-brand option. Walgreens also rolled out about 150 new items this summer despite shopper backlash.